

Opioid Treatment Best Practices DEA Requirement Online CE Course

Welcome and Course Overview <i>Benjamin Lai, M.B., B.Ch., B.A.O., Holly L. Geyer, M.D. & Casey M. Clements, M.D., Ph.D.</i>	
Safe Use of Opioids: Talks 1-8	
Current State: Guidelines, Regulations, Recommendations, and Challenges <i>Benjamin Lai, M.B., B.Ch., B.A.O.</i> <ul style="list-style-type: none"> • Discuss the current state of the opioid epidemic and how Covid-19 has affected it • Summarize current legislative efforts to control opioid prescribing • Synthesize current major guidelines, requirements, and laws regarding chronic opioid prescribing • Risk of opioid use disorder (OUD), tolerance & central sensitization/opioid-induced hyperalgesia with chronic opioid use 	ACPE Credit Number JA0000238-0000-23-134-H08-P <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div>
Opioid Prescribing Guidelines 2022: Updates and Summary of Changes <i>Casey M. Clements, M.D., Ph.D. & Robert W. Kirchoff, M.D., M.S.</i> <ul style="list-style-type: none"> • Describe the 2022 CDC opioid prescribing guidelines and highlight relevant changes • Review non-pharmacologic and non-opioid pain interventions • Understand approaches to patients with pain with focus on shared decision-making • Review screening and treatment options for opioid use disorder 	JA0000238-0000-23-134-H08-P <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div>
Opioid Stewardship: Careful Model of Patient Care <i>Holly L. Geyer, M.D.</i> <ul style="list-style-type: none"> • Review the data that compelled Mayo Clinic to establish an Opioid Stewardship Program (OSP) • Overview the process to establish an OSP • Examine the fundamental components of an OSP • Identify mechanism to monitor program success 	JA0000238-0000-23-134-H08-P <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div>
Opioid Pharmacology: Clinical Pearls <i>Julie L. Cunningham, Pharm D., R.Ph.</i> <ul style="list-style-type: none"> • Differentiate the clinically relevant pharmacology of various commonly used opioids • Identify rational opioid treatment choices based on patient and medication factors • Discuss place in therapy for low dose naltrexone (LDN) • Describe prevalence and risks of concurrent use of opioid with sedating agents 	JA0000238-0000-23-134-H08-P <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div>
Opioid-Related Endocrine Side Effects <i>Irina Bancos, M.D.</i> <ul style="list-style-type: none"> • Identify endocrine-related consequences in patients treated with chronic opioids • Diagnose and monitor opioid-related endocrinopathy • Provide treatment options for opioid-related endocrinopathy 	JA0000238-0000-23-134-H08-P <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div>
Safe Practices for Opioid Management in Older Adults <i>Daniel E. Sanchez Pellecer, M.D.</i>	JA0000238-0000-23-134-H08-P

<ul style="list-style-type: none"> • Learn a practical approach to assess pain in cognitively impaired older adults • Provide a general framework to use opioids in older adults by understanding its implications with geriatric syndromes • Review common opioid side effects in older adults 	<div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div>
<p>Acute Pain Management for the Patient on Chronic Opioids <i>Dare O. Olatoye, M.D.</i></p> <ul style="list-style-type: none"> • Discuss the clinical burden of patients on Chronic Opioid Therapy (COT) • Describe challenges associated with Chronic Opioid Therapy • Review acute pain management strategies of patients on Chronic Opioid Therapy 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; vertical-align: bottom;"> <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div> </div>
<p>Chronic Opioid Tapering: Pearls for the Primary Care Provider <i>Julie L. Cunningham, Pharm D., R.Ph.</i></p> <ul style="list-style-type: none"> • Review and discuss the evidence-based literature and guidelines regarding opioid tapering • Describe the primary risks associated with opioid tapering • Discuss opioid tapering tips, tricks, barriers, and pitfalls • Explain the tapering differences with the new CDC opioid prescribing guideline recommendations 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; vertical-align: bottom;"> <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div> </div>
Opioid Addiction: talks 9-18	
<p>Urine Drug testing & Patient Conversations <i>Benjamin Lai, M.B., B.Ch., B.A.O. & Loralie J. Langman, Ph.D.</i></p> <ul style="list-style-type: none"> • Integrate urine drug testing to support the treatment and monitoring of pain management patients • Describe the limitations of various screening and quantitative urine drug tests • Interpret urine drug testing results from pain management patients and patients with opioid use disorder on buprenorphine- naloxone • Apply the benefit-to-harm framework to help guide difficult conversations with patients about unexpected urine drug test results 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; vertical-align: bottom;"> <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div> </div>
<p>Drug Diversion Prevention and Substance Use Disorder Awareness – Creating a safe environment for our patients and staff- Part 1 <i>Alissa M. Voils, Pharm.D., R.Ph, M.H.A. & Wayne W. Hester, Jr.</i></p> <ul style="list-style-type: none"> • Define drug diversion and discuss how job and environmental stressors can lead to diversion and substance abuse in a healthcare setting. • Review typical diversion methods in a healthcare setting, including signs of potential diversion and how to escalate concerns. • Evaluate diversion risk points and share processes and systems at Mayo Clinic to ensure staff and patient safety when handling medications with a potential for diversion and abuse. • Share resources and support available to those struggling with substance abuse and seeking a path to recovery. 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; vertical-align: bottom;"> <div style="border: 1px solid black; padding: 2px; display: inline-block;">Rx</div> </div>
<p>Drug Diversion Prevention and Substance Use Disorder Awareness – Creating a safe environment for our patients and staff - Part 2 <i>Marlee A. Judd, APRN, CRNA, D.N.P. & Leanne L. Grangaard, M.S.N., R.N.</i></p>	<p>JA0000238-0000-23-134-H08-P</p>

<ul style="list-style-type: none"> Define drug diversion and discuss how job and environmental stressors can lead to diversion and substance abuse in a healthcare setting. Review typical diversion methods in a healthcare setting, including signs of potential diversion and how to escalate concerns. Evaluate diversion risk points and share processes and systems at Mayo Clinic to ensure staff and patient safety when handling medications with a potential for diversion and abuse. Share resources and support available to those struggling with substance abuse and seeking a path to recovery. 	<div style="text-align: right; border: 1px solid black; padding: 2px; width: fit-content; margin-left: auto;">Rx</div>
<p>Buprenorphine-Naloxone for Opioid Use Disorder: How to Do It? <i>Initiating Buprenorphine in the Outpatient Setting & in the Emergency Department</i> <i>Casey M. Clements, M.D., Ph.D. & Benjamin Lai, M.B., B.Ch., B.A.O.</i></p> <ul style="list-style-type: none"> Review the screening process for patients on chronic opioid therapy for opioid use disorder (OUD) Initiate OUD patients on buprenorphine –naloxone in the outpatient setting Initiate OUD patients on buprenorphine-naloxone in the Emergency Department setting 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; border: 1px solid black; padding: 2px; width: fit-content; margin-left: auto;">Rx</div>
<p>Buprenorphine: Use in Pain Management and Opioid Use Disorder- Part 1 And Part 2 <i>Mark E. Deyo-Svendsen, M.D.</i></p> <ul style="list-style-type: none"> Evaluate the hypothesis that buprenorphine is a good, and likely the best chronic opioid we have Apply new knowledge about buprenorphine to patients in your practice Develop a process that you will use to transition chronic opioid therapy patients to buprenorphine 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; border: 1px solid black; padding: 2px; width: fit-content; margin-left: auto;">Rx</div>
<p>How to Manage Acute Pain in Patients on Buprenorphine <i>Nafisseh S. Warner, M.D.</i></p> <ul style="list-style-type: none"> Describe the mechanism of action and unique properties of buprenorphine Understand the clinical indication for use Increase familiarity with acute pain and periprocedural management strategies for buprenorphine Understand the importance of multimodal and multidisciplinary care 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; border: 1px solid black; padding: 2px; width: fit-content; margin-left: auto;">Rx</div>
<p>Inpatient Initiation of Medication use for Opioid Use Disorder <i>Robert W. Kirchoff, M.D., M.S.</i></p> <ul style="list-style-type: none"> Recognize Opioid Use Disorder and opioid withdrawal Review medication options for Opioid Use Disorder (mOUD) Describe strategies for initiating mOUD in the hospital setting 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; border: 1px solid black; padding: 2px; width: fit-content; margin-left: auto;">Rx</div>
<p>Harm Reduction: Naloxone/New Illicit Drugs/Fentanyl Strips <i>Christopher J. Arendt, Pharm.D., R.Ph.</i></p> <ul style="list-style-type: none"> Discuss new formulations of naloxone and when to prescribe Address access to naloxone and implication of OTC status Describe the new worrisome illicit substances present and naloxone activity Describe other potential harm reduction strategies such as fentanyl strips and safe supply 	<p>JA0000238-0000-23-134-H08-P</p> <div style="text-align: right; border: 1px solid black; padding: 2px; width: fit-content; margin-left: auto;">Rx</div>

<p>Spirituality and Addiction - Part 1 and Part 2 <i>Brenda D. Kimery, P.A.-C.</i></p> <ul style="list-style-type: none"> • Spiritual Health <ul style="list-style-type: none"> ○ Define ○ Explain its role in opioid use disorder (OUD) and addiction medicine ○ Understand the concept of biopsychosocial-spiritual treatment model • Spiritual intervention/ integration in patients with OUD and addiction <ul style="list-style-type: none"> ○ Understand the medical evidence to support religious/spiritual integration into recovery and treatment ○ List the benefits of religion and spirituality in OUD management • Spiritual Assessment <ul style="list-style-type: none"> ○ Recall how to obtain a spiritual assessment ○ Identify spiritual needs and/or struggles in patients and why it is important 	<p>JA0000238-0000-23-134-H08-P</p>
<p>Medical Marijuana and CBD Products <i>Thomas P. Pittelkow, D.O., M.P.H.</i></p> <ul style="list-style-type: none"> • Identify the key cannabinoids, receptors and basic physiology of medical cannabis • Examine the current and future state of medical cannabis science • Articulate the role of medical cannabis in the pain treatment algorithm <ul style="list-style-type: none"> ○ Candidacy, monitoring and side effects 	<p>JA0000238-0000-23-134-H08-P</p> <div style="border: 1px solid black; width: 40px; height: 20px; margin-left: auto; margin-right: auto; text-align: center; line-height: 20px;">Rx</div>